MorphoSys Initiates Infectious Disease Alliance with ContraFect
Combinatorial Approach Using Multi-Therapy Antibody Treatment
Advertisement
MorphoSys AG announced the formation of a new alliance with US-based biotechnology company ContraFect Corp. in the discovery and development of therapeutic antibodies for infectious diseases. Under the terms of the five-year agreement, ContraFect will receive access to HuCAL PLATINUM, the latest and most powerful version of MorphoSys's antibody libraries, and AutoCAL at its facility in New York. Payments under the agreement include committed annual license fees in addition to success-based development milestones. MorphoSys also stands to receive royalties on sales of marketed drug products emerging from the collaboration.
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases, including MRSA infections and Influenza. ContraFect's scientific approach is based on a transition from conventional mono-therapy to a combinatorial approach using multi-therapy antibody treatment to address the growing challenge of drug resistance and therapy escape mechanisms.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous